A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
Status:
Completed
Trial end date:
2002-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, multicenter, comparative, and parallel-group study
comparing the therapeutic effects of two interferon-beta-1a regimens in relapsing-remitting
multiple sclerosis (MS). The primary objective is to demonstrate the superiority of Rebif® 44
microgram (mcg) subcutaneous injection given three times a week (132 mcg per week) to that of
Avonex® 30 mcg intramuscular injection given once a week.